TL;DR: Aetna, a CVS Health company, modified CPB 0830 governing hematopoietic cell transplantation for primary immunodeficiency disorders, effective December 10, 2025. Here's what billing teams need to act on now.
Aetna's hematopoietic cell transplantation coverage policy under CPB 0830 Aetna system now draws a sharper line between covered allogeneic transplants and procedures the payer considers experimental. The update affects CPT codes 38205, 38230, 38240, 38232, and 38241, plus HCPCS S2150. If your team bills transplant services for immunodeficiency patients under Aetna plans, this policy change directly determines what gets paid and what gets denied.
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Hematopoietic Cell Transplantation for Primary Immunodeficiency Disorders |
| Policy Code | CPB 0830 |
| Change Type | Modified |
| Effective Date | December 10, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology/Oncology, Pediatric Immunology, Bone Marrow Transplant Programs, Allergy/Immunology |
| Key Action | Audit all pending and upcoming HCT authorizations against the updated covered and excluded indication lists before billing |
Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025
Aetna's coverage policy on HCT for primary immunodeficiency disorders is built around one central distinction: allogeneic transplants for a defined list of PIDs clear the medical necessity bar; autologous transplants do not, for any PID indication.
For allogeneic HCT, Aetna considers CPT 38205 (allogeneic blood-derived progenitor cell harvesting), CPT 38230 (allogeneic bone marrow harvesting), CPT 38240 (allogeneic HPC transplantation per donor), and HCPCS S2150 (allogeneic bone marrow or blood-derived stem cells) covered when selection criteria are met. The list of covered conditions is long — 23 specific diagnoses — and includes some conditions you may not see often, like Griscelli syndrome type 2, ZAP-70 deficiency, and IL-10 receptor deficiency.
The covered PID list under this coverage policy includes:
| # | Covered Indication |
|---|---|
| 1 | Adenosine deaminase deficiency |
| 2 | Autoimmune lymphoproliferative syndrome |
| 3 | Cartilage hair hypoplasia |
| 4 | CD40 ligand deficiency |
| 5 | Chediak-Higashi syndrome (ICD-10 E70.330) |
| 6 | Chronic granulomatous disease |
| 7 | Common variable immune deficiency (CVID) — ICD-10 D83.9 |
| 8 | DiGeorge syndrome — ICD-10 D82.1 |
| 9 | Griscelli syndrome type 2 |
| 10 | Hemophagocytic lymphohistiocytosis — ICD-10 D76.1 |
| 11 | IL-10 receptor deficiency |
| 12 | IPEX syndrome — ICD-10 E34.8 |
| 13 | Kostmann syndrome / severe congenital neutropenia type 3 |
| 14 | Leukocyte adhesion deficiency type 1 — ICD-10 D84.81–D84.89 |
| 15 | MHC class I deficiency — ICD-10 D81.6 |
| 16 | MHC class II deficiency |
| 17 | Purine nucleoside phosphorylase deficiency — ICD-10 D81.5 |
| 18 | Severe combined immunodeficiency (SCID) — ICD-10 D81.0, D81.1, D81.2, D81.9 |
| 19 | Severe congenital neutropenia — ICD-10 D70.0 |
| 20 | Wiskott-Aldrich syndrome — ICD-10 D82.0 |
| 21 | WAS X-linked thrombocytopenia — ICD-10 D69.42 |
| 22 | X-linked lymphoproliferative syndrome — ICD-10 D82.3 |
| 23 | ZAP-70 deficiency |
One specific add-on also clears medical necessity: T-cell receptor excision circle (TREC) testing following allogeneic hematopoietic stem cell transplant for SCID. If your program performs post-transplant TREC monitoring for SCID patients, document that indication clearly on the claim.
Aetna hematopoietic cell transplantation billing also requires that you distinguish the harvesting codes from the transplantation codes in your charge capture. CPT 38205 and 38230 cover the collection and harvesting side. CPT 38240 and HCPCS S2150 cover the transplantation itself. These are separate billable events, and conflating them creates reimbursement problems.
Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications
This is where the policy gets expensive if your team isn't paying attention. Aetna labels six specific indications experimental, investigational, or unproven for allogeneic HCT — and adds a blanket exclusion on autologous HCT across all PID indications.
The six conditions excluded from allogeneic HCT coverage are:
| # | Excluded Procedure |
|---|---|
| 1 | Activated phosphoinositide 3-kinase delta syndrome (APDS) |
| 2 | Complement deficiency — ICD-10 D84.1 |
| 3 | Granulomatous-lymphocytic interstitial lung disease — ICD-10 J84.89 |
| 4 | Inflammatory bowel disease (Crohn's K50.00–K50.919, ulcerative colitis K51.00–K51.919) |
| 5 | Juvenile idiopathic arthritis — ICD-10 M08 code range |
| 6 | Pulmonary alveolar proteinosis — ICD-10 J84.01 |
The real issue here is APDS. It's a recently characterized PID caused by gain-of-function mutations in PI3Kδ. Clinicians sometimes consider allogeneic HCT for severe cases. Aetna's position is clear: experimental. If you're seeing APDS referrals for transplant workup, flag this before the procedure, not after.
Autologous HCT is excluded across the board. CPT 38232 (autologous bone marrow harvesting) and CPT 38241 (autologous HPC transplantation) are not covered for any PID indication under this policy. Full stop. Don't build a case for autologous reimbursement under CPB 0830 — Aetna's coverage policy doesn't leave room for it.
IBD as a PID transplant indication is the one that probably generates the most incorrect prior auth submissions. Crohn's disease and ulcerative colitis patients sometimes carry secondary immune dysregulation diagnoses. If the primary indication for HCT is IBD, the claim fails under this policy. Document the primary indication carefully.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| SCID (all subtypes) | Covered | D81.0, D81.1, D81.2, D81.9; CPT 38240, 38205, 38230 | TREC testing post-transplant also covered |
| Wiskott-Aldrich syndrome | Covered | D82.0; CPT 38240, 38230 | Allogeneic only |
| WAS X-linked thrombocytopenia | Covered | D69.42 | Allogeneic only |
| Adenosine deaminase deficiency | Covered | D81.30–D81.39 | Multiple ADA deficiency subtypes covered |
| Common variable immune deficiency | Covered | D83.9 | Allogeneic only |
| DiGeorge syndrome | Covered | D82.1 | Allogeneic only |
| Hemophagocytic lymphohistiocytosis | Covered | D76.1 | Allogeneic only |
| Chediak-Higashi syndrome | Covered | E70.330 | Allogeneic only |
| Chronic granulomatous disease | Covered | D71.1, D71.8, D71.9 | Allogeneic only |
| Leukocyte adhesion deficiency type 1 | Covered | D84.81–D84.89 | Allogeneic only |
| MHC class I deficiency | Covered | D81.6 | Allogeneic only |
| Purine nucleoside phosphorylase deficiency | Covered | D81.5 | Allogeneic only |
| IPEX syndrome | Covered | E34.8 | Allogeneic only |
| X-linked lymphoproliferative syndrome | Covered | D82.3 | Allogeneic only |
| Autoimmune lymphoproliferative syndrome | Covered | D89.82 | Allogeneic only |
| Kostmann syndrome / severe congenital neutropenia | Covered | D70.0 | Allogeneic only |
| IL-10 receptor deficiency | Covered | (refer to applicable D84 codes) | Allogeneic only |
| Griscelli syndrome type 2 | Covered | (refer to applicable ICD-10) | Allogeneic only |
| Cartilage hair hypoplasia | Covered | (refer to applicable ICD-10) | Allogeneic only |
| CD40 ligand deficiency | Covered | D80.5 | Allogeneic only |
| ZAP-70 deficiency | Covered | (refer to applicable ICD-10) | Allogeneic only |
| TREC testing post-transplant for SCID | Covered | D81.0, D81.1, D81.2, D81.9 | Post-allogeneic HCT only |
| Activated PI3Kδ syndrome (APDS) | Experimental | — | Allogeneic HCT not covered |
| Complement deficiency | Experimental | D84.1 | Allogeneic HCT not covered |
| Granulomatous-lymphocytic interstitial lung disease | Experimental | J84.89 | Allogeneic HCT not covered |
| Inflammatory bowel disease | Experimental | K50.00–K50.919, K51.00–K51.919 | Allogeneic HCT not covered |
| Juvenile idiopathic arthritis | Experimental | M08.0–M08.99 range | Allogeneic HCT not covered |
| Pulmonary alveolar proteinosis | Experimental | J84.01 | Allogeneic HCT not covered |
| All PID indications — autologous HCT | Not Covered | CPT 38232, 38241 | Blanket exclusion; no exceptions |
Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit every open HCT authorization before December 10, 2025. The effective date is December 10, 2025. Any authorization tied to an excluded indication — especially APDS, complement deficiency, or IBD — needs to be reviewed and corrected before that date. Don't wait for a claim denial to surface the problem. |
| 2 | Remove CPT 38232 and 38241 from your HCT charge capture for PID patients. Autologous harvesting and transplantation codes are not covered under this policy for any PID indication. If these codes appear on your charge description master for PID pathways, pull them. Billing them against an Aetna plan in this context will generate denials. |
| 3 | Map each covered PID diagnosis to its correct ICD-10 code before submission. The ADA deficiency code family alone runs from D81.30 through D81.39. Leukocyte adhesion deficiency type 1 spans D84.81 through D84.89. Using an unspecified code when a more specific one exists gives Aetna a reason to question medical necessity. Be precise. |
| 4 | Separate harvesting and transplantation on your claims. CPT 38205 and 38230 cover the collection side. CPT 38240 covers the actual transplant per donor. HCPCS S2150 covers the stem cells themselves. These are distinct billable events. Bundling them incorrectly — or missing one — leaves reimbursement on the table. |
| 5 | Document TREC testing indications explicitly for post-SCID-transplant claims. TREC testing is covered specifically as a follow-up tool after allogeneic HCT for SCID. The documentation supporting the claim should state the test is post-transplant monitoring for SCID — not general immune function testing. The medical necessity standard is narrow here. |
| 6 | Flag APDS patients immediately. Activated PI3Kδ syndrome is increasingly recognized, and transplant programs are seeing more referrals. Aetna calls it experimental under this policy. If your team has pending requests for APDS patients, talk to your compliance officer and the treating physician before December 10, 2025. An appeals strategy requires planning, not a reaction to denial. |
| 7 | Review your billing guidelines with payers for non-Aetna plans. This policy is Aetna-specific. Other commercial payers may cover indications Aetna excludes — or restrict ones Aetna covers. Don't assume this coverage policy maps to Cigna, UnitedHealthcare, or your regional BCBS plans. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0830
Covered CPT and HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 38205 | CPT | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, allogeneic |
| 38230 | CPT | Bone marrow harvesting for transplantation; allogeneic |
| 38240 | CPT | Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor |
| S2150 | HCPCS | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvest and transplantation |
Not Covered Codes — All PID Indications
| Code | Type | Description | Reason |
|---|---|---|---|
| 38232 | CPT | Bone marrow harvesting for transplantation; autologous | Not covered for any PID indication |
| 38241 | CPT | Hematopoietic progenitor cell (HPC); autologous transplantation | Not covered for any PID indication |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| D69.42 | Congenital and hereditary thrombocytopenia purpura |
| D70.0 | Congenital agranulocytosis |
| D71.1 | Functional disorders of polymorphonuclear neutrophils |
| D71.8 | Functional disorders of polymorphonuclear neutrophils |
| D71.9 | Functional disorders of polymorphonuclear neutrophils |
| D76.1 | Hemophagocytic lymphohistiocytosis |
| D80.5 | Immunodeficiency with increased immunoglobulin M [IgM] |
| D81.0 | Severe combined immunodeficiency [SCID] with reticular dysgenesis |
| D81.1 | Severe combined immunodeficiency [SCID] with low T- and B-cell numbers |
| D81.2 | Severe combined immunodeficiency [SCID] with low or normal B-cell numbers |
| D81.30 | Adenosine deaminase [ADA] deficiency |
| D81.31 | Adenosine deaminase [ADA] deficiency |
| D81.32 | Adenosine deaminase [ADA] deficiency |
| D81.33 | Adenosine deaminase [ADA] deficiency |
| D81.34 | Adenosine deaminase [ADA] deficiency |
| D81.35 | Adenosine deaminase [ADA] deficiency |
| D81.36 | Adenosine deaminase [ADA] deficiency |
| D81.37 | Adenosine deaminase [ADA] deficiency |
| D81.38 | Adenosine deaminase [ADA] deficiency |
| D81.39 | Adenosine deaminase [ADA] deficiency |
| D81.5 | Purine nucleoside phosphorylase [PNP] deficiency |
| D81.6 | Major histocompatibility complex class I deficiency |
| D81.9 | Combined immunodeficiency, unspecified |
| D82.0 | Wiskott-Aldrich syndrome |
| D82.1 | DiGeorge's syndrome |
| D82.3 | Immunodeficiency following hereditary defective response to Epstein-Barr virus |
| D83.9 | Common variable immune deficiency |
| D84.1 | Defects in the complement system (experimental indication) |
| D84.81 | Other specified immunodeficiencies [leukocyte adhesion deficiency type 1] |
| D84.82 | Other specified immunodeficiencies [leukocyte adhesion deficiency type 1] |
| D84.83 | Other specified immunodeficiencies [leukocyte adhesion deficiency type 1] |
| D84.84 | Other specified immunodeficiencies [leukocyte adhesion deficiency type 1] |
| D84.85 | Other specified immunodeficiencies [leukocyte adhesion deficiency type 1] |
| D84.86 | Other specified immunodeficiencies [leukocyte adhesion deficiency type 1] |
| D84.87 | Other specified immunodeficiencies [leukocyte adhesion deficiency type 1] |
| D84.88 | Other specified immunodeficiencies [leukocyte adhesion deficiency type 1] |
| D84.89 | Other specified immunodeficiencies [leukocyte adhesion deficiency type 1] |
| D89.82 | Autoimmune lymphoproliferative syndrome |
| E34.8 | Other specified endocrine disorders [IPEX] |
| E70.330 | Chediak-Higashi syndrome |
| J84.01 | Alveolar proteinosis (experimental indication) |
| J84.89 | Other specified interstitial pulmonary diseases [granulomatous-lymphocytic interstitial lung disease] (experimental indication) |
| K50.00–K50.919 | Crohn's disease [regional enteritis] (experimental indication) |
| K51.00–K51.919 | Ulcerative colitis (experimental indication) |
| M08.0–M08.29 and extended range | Juvenile idiopathic arthritis codes (experimental indication) |
Get the Full Picture for CPT 38205
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.